The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts and trial observations without systematic review methodology or new human data.
PubMed 39754177 · doi:10.1186/s13072-024-00564-4
What was done
This review synthesized current mechanistic and clinical literature addressing barriers to HIV cure strategies, focusing on viral genetic diversity, epigenetic regulation of viral latency, RNA modifications such as N6-methyladenosine methylation, chromatin dynamics, and biological sex differences.
What was found
The abstract reports no quantitative values or statistical metrics. Qualitatively, it highlights that the first-in-human trial of the CRISPR-based candidate EBT-101 demonstrated safety but did not prevent viral rebound. Latency-reversing agents (LRAs) remain clinically limited by reservoir heterogeneity, while post-transcriptional RNA modifications and chromatin remodeling regulate latency and reactivation. Additionally, females exhibit stronger early immune responses and higher representation among elite controllers.
Why it matters
Understanding the convergence of epigenetic latency, RNA regulation, and sex-specific immune differences is necessary to guide more effective combinatorial strategies for HIV eradication.
Limits
As a narrative review, it presents no original empirical data, systematic search criteria, or quantitative synthesis. The abstract reports no sample sizes or numerical effect sizes.
Cited by
- supports CRISPR gene editing is being evaluated in clinical trials as a potential cure for HIV infection.